Fine specificity of the antibody response to Epstein-Barr nuclear antigen-2 and other Epstein-Barr virus proteins in patients with clinically isolated syndrome: a peptide microarray-based case-control study

Tools

Item Type:	Article
Title:	Fine specificity of the antibody response to Epstein-Barr nuclear antigen-2 and other Epstein-Barr virus proteins in patients with clinically isolated syndrome: a peptide microarray-based case-control study
Creators Name:	Schlemm, L., Giess, R.M., Rasche, L., Pfuhl, C., Wakonig, K., Behrens, J.R., Scheibenbogen, C., Bellmann-Strobl, J., Paul, F., Reimer, U. and Ruprecht, K.
Abstract:	We analyzed the fine specificity of antibodies to Epstein-Barr nuclear antigen-2 (EBNA-2) and other Epstein-Barr virus (EBV) proteins in 29 patients with clinically isolated syndrome (CIS, the first clinical manifestation of multiple sclerosis [MS]) and 29 controls with a peptide microarray containing 117 overlapping peptides representing the full-length EBNA-2 protein and 71 peptides from 8 further EBV proteins. While EBV peptide antibodies were elevated in CIS, suggesting that EBV contributes to MS early during disease development, they discriminated groups only slightly better than EBNA-1 antibodies. Thus, the additional value of EBV peptide antibodies as diagnostic biomarkers for CIS appears moderate.
Keywords:	Multiple Sclerosis, Clinically Isolated Syndrome, Epstein-Barr Virus, Epstein-Barr Nuclear Antigen, Antibodies, Peptide Microarray, Animals, Mice
Source:	Journal of Neuroimmunology
ISSN:	0165-5728
Publisher:	Elsevier
Volume:	297
Page Range:	56-62
Date:	15 August 2016
Official Publication:	https://doi.org/10.1016/j.jneuroim.2016.05.012
PubMed:	View item in PubMed

Repository Staff Only: item control page